- Home
- STSS
as 10-21-2025 3:55pm EST
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | MELVILLE |
| Market Cap: | 186.3M | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | 689.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.36 - $1248.27 | Next Earning Date: | 11-13-2025 |
| Revenue: | $222,722 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Sharps Technology Inc. News
STSS Breaking Stock News: Dive into STSS Ticker-Specific Updates for Smart Investing
Simply Wall St.
10 days ago
Can Coinbase (COIN) Leverage Growing Institutional SOL Demand to Strengthen Its Crypto Custody Edge?
Cryptonews
12 days ago
Sharps Technology Moves $435M Solana Treasury to Coinbase — Will It Top Rivals?
PR Newswire
13 days ago
Sharps Technology Expands Digital Asset Treasury Strategy with Coinbase
Cryptonews
15 days ago
Nasdaq-Listed Solana Company Grows Treasury to $525M in SOL Holdings – Solana About to Explode?
ACCESS Newswire
15 days ago
New to The Street to Broadcast Tonight on Fox Business 10:30 PM PST Featuring NeOnc Technologies, FLOKI, XION, Sharps Technology, and Aeries Technology
Cryptonews
19 days ago
Sharps Technology Unveils $100M Solana Buyback – Are Treasury Firms Turning Sour on SOL?
Benzinga
20 days ago
Sharps Technology Teams Up With Crypto.com To Grow Solana Strategy
MT Newswires
20 days ago
Sharps Technology Launches Up to $100 Million Stock Repurchase Plan
Compare STSS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STSS Sharps Technology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.